Humira use in pJIA extended

The licence for Humira (adalimumab) in polyarticular juvenile idiopathic arthritis (pJIA) has been extended to include the treatment of children from 4 years-old. Humira can be given in combination with methotrexate when the response to one or more DMARDs is inadequate, or as monotherapy if methotrexate is inappropriate or not tolerated.

The recommended dose is 24mg/m2 (max 40mg) by subcutaneous injection every other week. To enable accurate dosing, Humira solution for injection is now available as a vial, in addition to the prefilled pen and syringe presentations.

View Humira drug record

Further Information: Abbott Laboratories Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Early emollient use does not prevent eczema in children

Early emollient use does not prevent eczema in children

Daily application of emollients in infancy is not effective...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Macrolide prescribing in pregnancy linked to risk of birth defects

Macrolide prescribing in pregnancy linked to risk of birth defects

Researchers have called for caution when prescribing...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Ativan and penicillamine.
Use our constantly...